New agents in intravesical chemotherapy of superficial bladder cancer.

Article Details

Citation

Copy to clipboard

Perabo FG, Muller SC

New agents in intravesical chemotherapy of superficial bladder cancer.

Scand J Urol Nephrol. 2005;39(2):108-16.

PubMed ID

16019763 [ View in PubMed

]

Abstract

Although intravesical chemotherapy has been used in the management of superficial bladder cancer for some decades, until recently there has been little or no progress in the search for new agents. However, in the past few years there have been developments of investigational drugs that may play a future role in this indication. This review highlights the mode of action, indications, dose and administration, efficacy, safety and significance of new chemotherapeutic agents such as intravesical valrubicin, gemcitabine, suramin, gamma-linolenic acid, eflornithine (DFMO), tipifarnib (R115777), fenritinide and celecoxib. Although the initial results achieved with these agents in clinical development seem encouraging, long-term data on the prevention of recurrence, disease progression and survival have yet to be obtained.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Valrubicin	DNA	Nucleotide	Humans	Yes	Intercalation	Details
Valrubicin	DNA topoisomerase 2-alpha	Protein	Humans	Yes	Inhibitor	Details